Dataset Information


Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.

ABSTRACT: Vemurafenib and dabrafenib block MEK-ERK1/2 signaling and cause tumor regression in the majority of advanced-stage BRAF(V600E) melanoma patients; however, acquired resistance and paradoxical signaling have driven efforts for more potent and selective RAF inhibitors. Next-generation RAF inhibitors, such as PLX7904 (PB04), effectively inhibit RAF signaling in BRAF(V600E) melanoma cells without paradoxical effects in wild-type cells. Furthermore, PLX7904 blocks the growth of vemurafenib-resistant BRAF(V600E) cells that express mutant NRAS. Acquired resistance to vemurafenib and dabrafenib is also frequently driven by expression of mutation BRAF splice variants; thus, we tested the effects of PLX7904 and its clinical analog, PLX8394 (PB03), in BRAF(V600E) splice variant-mediated vemurafenib-resistant cells. We show that paradox-breaker RAF inhibitors potently block MEK-ERK1/2 signaling, G1/S cell cycle events, survival and growth of vemurafenib/PLX4720-resistant cells harboring distinct BRAF(V600E) splice variants. These data support the further investigation of paradox-breaker RAF inhibitors as a second-line treatment option for patients failing on vemurafenib or dabrafenib.


PROVIDER: S-EPMC3988223 | BioStudies | 2014-01-01

REPOSITORIES: biostudies

Similar Datasets

2013-01-01 | S-EPMC3695051 | BioStudies
2015-10-01 | GSE71109 | GEO
2016-01-01 | S-EPMC5115767 | BioStudies
2016-01-01 | S-EPMC4812324 | BioStudies
2017-01-01 | S-EPMC5490236 | BioStudies
2014-01-01 | S-EPMC4020954 | BioStudies
2018-01-01 | S-EPMC5752590 | BioStudies
2013-01-01 | S-EPMC3606893 | BioStudies
2017-01-01 | S-EPMC6000833 | BioStudies
2011-01-01 | S-EPMC3266695 | BioStudies